Podcast Pearls: Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer

Download this slideset to learn more about the rationale for combining PARP inhibitors with a variety of agents including androgen receptor directed therapy, immune checkpoint inhibitors, and DNA damaging agents as discussed in our podcast.
Karim Fizazi, MD, PhD
Joaquin Mateo, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.13 MB
Released: April 16, 2021


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Pfizer Inc.

Related Content

Expert insight from Arjun Balar, MD, on choosing optimal therapy for patients with advanced urothelial cancer after chemo and IO, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 4, 2021 Expired: May 3, 2022

Slides from Arjun Balar, MD on the role of antibody-drug conjugates in early stage urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: May 4, 2021

Clinical Care Options (CCO) commentary of expert insights on FGFR alterations and targeted therapies for bladder and urothelial carcinoma

Andrea Necchi, MD Released: April 30, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.